Author:
Zhang Lei,Yu Lu,Xu Yanpeng,Qin Peilan,Shen Pengcheng,Liu Kemeng,Fei Mengdan,Wang Hongya,Cao Yanjing,Lu Lihong,Gao Wenyuan,Zhang Zhongli
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry,Analytical Chemistry
Reference45 articles.
1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. https://doi.org/10.1038/nrd1381.
2. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1–14. https://doi.org/10.1111/j.1365-2710.2007.00800.x.
3. U.S. Food and Drug administration (FDA). Avastin® (bevacizumab) prescribing information, Genentech, Inc., San Francisco, CA, USA 2004. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_Approv.pdf. Accessed 4 May 2023.
4. Seo N, Polozova A, Zhang MX, Yates Z, Cao S, Li HM, Kuhns S, Maher G, McBride HJ, Liu J. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018;10(4):678–91. https://doi.org/10.1080/19420862.2018.1452580.
5. Bellinvia S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. Expert Opin Drug Discov. 2020;15(11):1–7. https://doi.org/10.1080/17460441.2020.1796627.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献